Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

ElliottwaveForecast Jun. 29 at 9:05 AM

$JNJ favors rally towards 271.4 in daily It managed to break to new high in daily from #bluebox area as anticipated. Short term pullback in 3, 7 or 11 swings against 6.22.2026 low should remain supported to continue rally in ((5)). #Elliottwave #JNJ

0 · Reply

JoshAlphaOne Jun. 29 at 8:23 AM

🐢 $JNJ Swing Setup Johnson & Johnson just broke out of a multi-month base. Entry Zone: $248.19 – $254.66 Stop: Below $220.84 Target 1: $305.59 Target 2: $381.99 Healthcare rotation heating up + political tailwinds. Patience on the pullback. Trend is intact.

0 · Reply

howardlindzon Jun. 29 at 2:13 AM

$XBI up 7 percxent since I added to my portfolio and shared now $XLV coming to the party after being a dog the last year it was the BEST EVER relaive week for healtcare relative to $SPY https://x.com/ThierryBorgeat/status/2071315993649934707 the narrative is key and i assume it will be - 'look how much these companies can save deploying ai to fast track research yada yada yada and a lot of this will be true. I chose index because I have no clue how to pick stocks in this sector wiuth conviction other than Eli Lily with the clear lead in fat pills/needles (I am a customer). so what happened last week $LLY all time high, $JNJ all time high and Merck near one. the degenerates will surely learn the tickers if the priuces keep going up as they did with NFT's and crypto and ai and space Im old and boring for now with the diversified index Genomics breaking out too

0 · Reply

RaddyRad Jun. 29 at 12:44 AM

$SLS all day......$LLY $MRK $ABBV $JNJ

1 · Reply

FibonacciTrader_ Jun. 28 at 9:11 PM

Healthcare is starting to wake up again. $LLY $MRK $UNH $JNJ We’re seeing multiple names transition from long bases into early breakout structures. $LLY clearing an 8-month consolidation on expanding volume $MRK building a massive multi-year base $UNH still holding a clean Stage 2 uptrend structure $JNJ pushing into new all-time highs with steady institutional demand When multiple leaders in one sector start moving together, it usually signals rotation-not isolated strength. This looks less like individual breakouts and more like a sector-wide expansion phase forming underneath the surface.

0 · Reply

vu_jade Jun. 28 at 4:44 PM

$VKTX Maybe it’s time for $JNJ to make a nice acquisition … #SKOL

2 · Reply

BioTechHealthX Jun. 28 at 7:25 AM

$JNJ Johnson & Johnson (JNJ) may be one of the oldest names in healthcare, but its MedTech launches, innovative medicine portfolio, institutional backing, and AI-powered healthcare potential show why this blue-chip healthcare stock still deserves serious investor attention. https://biotechhealthx.com/biotech-news/is-johnson-johnson-jnj-still-one-of-the-safest-healthcare-stocks-to-buy/

0 · Reply

BioTechHealthX Jun. 28 at 6:11 AM

$REGN $JNJ $LLY $PFE $SYK Artificial intelligence is no longer just a tech story. These healthcare stocks are using AI, automation, digital platforms, and advanced medical tools to improve clinical workflows, diagnostics, drug development, and patient outcomes. https://biotechhealthx.com/biotech-news/top-5-ai-powered-healthcare-stocks-that-can-make-you-rich/

0 · Reply

chalz_joshua_ Jun. 27 at 11:09 PM

$JNJ 🔥🔥📈

0 · Reply

Tetoooo Jun. 27 at 10:55 PM

$JNJ I run triple AI models GPT, GIMINAI, and Claude to analyze this stock with http://TrioVate.ai it is free

0 · Reply

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

2026-06-26T16:40:11.000Z - 2 days ago

Johnson & Johnson presents new Imaavy data at EAN 2026 Congress

Jun 26, 2026, 12:35 PM EDT - 2 days ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

2026-06-26T12:36:03.000Z - 2 days ago

Johnson & Johnson price target raised to $270 from $266 at Guggenheim

2026-06-25T09:10:22.000Z - 4 days ago

Johnson & Johnson launches Dual Energy Thermocool Smarttouch in Europe

Jun 25, 2026, 5:00 AM EDT - 4 days ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

2026-06-16T20:26:11.000Z - 12 days ago

3 Strong Buy Dividend Aristocrat Stocks, According to Top Analysts — June 16, 2026

AMCR LOW

2026-06-15T11:17:46.000Z - 13 days ago

Johnson & Johnson (JNJ) Boosts Eye Care Business in $55B U.S. Manufacturing Push

2026-06-15T10:05:07.000Z - 13 days ago

Johnson & Johnson invests more than $1B in Jacksonville, Florida

Jun 15, 2026, 6:00 AM EDT - 13 days ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

$New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:41 AM EDT - 15 days ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

$New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:33 AM EDT - 15 days ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

2026-06-11T11:50:10.000Z - 17 days ago

Johnson & Johnson expands U.S. availability of TECNIS PureSee IOL

Jun 11, 2026, 7:45 AM EDT - 17 days ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 7:14 AM EDT - 17 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE KYMR

2026-06-11T09:26:54.000Z - 18 days ago

Johnson & Johnson presents first results from ENERGY study

Jun 11, 2026, 2:03 AM EDT - 18 days ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 10, 2026, 11:22 AM EDT - 18 days ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 6:20 AM EDT - 18 days ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 9, 2026, 10:00 AM EDT - 19 days ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 9:20 AM EDT - 19 days ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Jun 8, 2026, 9:01 AM EDT - 20 days ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

2026-06-08T13:00:56.000Z - 20 days ago

M&A News: Johnson & Johnson (JNJ) Reaches a Massive $1B Deal for Firefly Bio to Expand Its Oncology Pipeline

2026-06-08T12:14:56.000Z - 20 days ago

Johnson & Johnson to acquire Firefly Bio for $1B in cash

Jun 8, 2026, 8:08 AM EDT - 20 days ago

Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:00 AM EDT - 20 days ago

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Jun 5, 2026, 6:24 PM EDT - 23 days ago

J&J beats lawsuit alleging that talc caused three women's cancer

Jun 3, 2026, 12:04 AM EDT - 26 days ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

SLE

Jun 3, 2026, 12:03 AM EDT - 26 days ago

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jun 2, 2026, 6:24 PM EDT - 26 days ago

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

JPM KMB MCD YUM

May 31, 2026, 8:39 AM EDT - 4 weeks ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

May 31, 2026, 8:29 AM EDT - 4 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

May 31, 2026, 8:27 AM EDT - 4 weeks ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

May 31, 2026, 8:01 AM EDT - 4 weeks ago

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

May 29, 2026, 2:00 PM EDT - 4 weeks ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

May 29, 2026, 8:18 AM EDT - 4 weeks ago

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

May 28, 2026, 7:10 PM EDT - 4 weeks ago

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

May 28, 2026, 5:30 AM EDT - 4 weeks ago

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

May 27, 2026, 4:22 PM EDT - 4 weeks ago

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

May 27, 2026, 11:00 AM EDT - 4 weeks ago

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 21, 2026, 7:00 AM EDT - 5 weeks ago

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

May 21, 2026, 4:31 AM EDT - 5 weeks ago

Johnson & Johnson says nipocalimab approved in China

May 19, 2026, 11:30 AM EDT - 5 weeks ago

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 9:00 AM EDT - 5 weeks ago

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

May 14, 2026, 4:01 PM EDT - 6 weeks ago

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

STGW

May 12, 2026, 2:20 PM EDT - 6 weeks ago

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 7:45 AM EDT - 6 weeks ago

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

May 11, 2026, 4:34 PM EDT - 6 weeks ago

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 11, 2026, 8:00 AM EDT - 6 weeks ago

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

May 7, 2026, 11:34 AM EDT - 7 weeks ago

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

May 7, 2026, 8:00 AM EDT - 7 weeks ago

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

May 5, 2026, 9:15 AM EDT - 7 weeks ago

CVS to drop J&J's Stelara from its main formularies

CVS

May 5, 2026, 8:05 AM EDT - 7 weeks ago

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

$Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease$

May 5, 2026, 8:05 AM EDT - 7 weeks ago

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

May 5, 2026, 7:00 AM EDT - 7 weeks ago

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

May 4, 2026, 8:00 AM EDT - 7 weeks ago

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

May 2, 2026, 4:00 AM EDT - 2 months ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

Apr 30, 2026, 8:02 AM EDT - 2 months ago

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Apr 28, 2026, 11:10 AM EDT - 2 months ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM

Apr 27, 2026, 4:33 PM EDT - 2 months ago

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

Apr 27, 2026, 11:03 AM EDT - 2 months ago

J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 8:03 AM EDT - 2 months ago

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Apr 24, 2026, 4:30 PM EDT - 2 months ago

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

Apr 23, 2026, 6:44 PM EDT - 2 months ago

Cramer says look to these 4 stocks to go with your high-flying tech names

CAH CVS UNH

ElliottwaveForecast Jun. 29 at 9:05 AM

0 · Reply

JoshAlphaOne Jun. 29 at 8:23 AM

0 · Reply

howardlindzon Jun. 29 at 2:13 AM

0 · Reply

RaddyRad Jun. 29 at 12:44 AM

$SLS all day......$LLY $MRK $ABBV $JNJ

1 · Reply

FibonacciTrader_ Jun. 28 at 9:11 PM

0 · Reply

vu_jade Jun. 28 at 4:44 PM

$VKTX Maybe it’s time for $JNJ to make a nice acquisition … #SKOL

2 · Reply

BioTechHealthX Jun. 28 at 7:25 AM

0 · Reply

BioTechHealthX Jun. 28 at 6:11 AM

0 · Reply

chalz_joshua_ Jun. 27 at 11:09 PM

$JNJ 🔥🔥📈

0 · Reply

Tetoooo Jun. 27 at 10:55 PM

$JNJ I run triple AI models GPT, GIMINAI, and Claude to analyze this stock with http://TrioVate.ai it is free

0 · Reply

howardlindzon Jun. 27 at 10:46 PM

$JNJ wow all time highs. bandaids

4 · Reply

CosmicMiner Jun. 27 at 10:37 PM

$JNJ has been incredibly strong, surging to $254.66 and hitting a new 52-week high! As a healthcare giant, its robust pharma pipeline and med-tech growth are drawing heavy defensive inflows. This rally looks solid.

1 · Reply

KryptonResearch Jun. 27 at 10:14 PM

While markets are extremely focused on the inputs to the AI trade (and for good reason, as this is where the capital is flowing at the present moment). We take a look at the flip side of the AI trade. Those using AI to accelerate their businesses. Today’s investment is one of our favorites. A great business and revolutionary technology, but more importantly, one that is going to transform the lives of billions. $LLY $NVO $ABBV $PFE $JNJ Take a read: https://kryptonresearch.substack.com/p/blood-money

0 · Reply

FibonacciTrader_ Jun. 27 at 10:03 PM

Rotation is doing exactly what it usually does late-cycle- money stops chasing momentum and starts hiding in defensives with visible cash flows. This week the tape flipped hard: $ABBV +17% | pharma leadership catching bid on defensive + yield rotation $MRK +13% | large-cap healthcare strength as risk appetite fades $JNJ +12% | classic safety trade back in favor $DHR +11% | life sciences tools seeing steady institutional demand $LLY +10% | still strong structurally, but now part of broader defensive bid Meanwhile semis are cooling as AI beta unwinds from stretched positioning. This isn’t “AI is dead” pricing. It’s capital rotating from narrative to stability. When healthcare leads and semis lag, the market is telling you one thing: risk is being reduced, not added

0 · Reply

CapitalLogic1 Jun. 27 at 9:07 PM

$JNJ still trending in a slow, steady way. No real volatility here, just consistent grinding higher without much attention. Moves feel orderly, more like a defensive name just doing its thing while the rest of the market swings around.

0 · Reply

WhaleTracker_ Jun. 27 at 2:10 PM

This week’s tape rotation is pretty clear - AI and semis took a breather, while defensives quietly led. 1-week returns: $ABBV +17% (AbbVie) $MRK +13% (Merck) $JNJ +12% (Johnson & Johnson) $DHR +11% (Danaher) $LLY +10% (Eli Lilly) What stands out isn’t just performance, but leadership shifting into healthcare while high-beta growth cooled off. This kind of rotation usually says more about positioning stress than any single macro headline - when crowded trades unwind, capital doesn’t disappear, it just moves.

0 · Reply

Bjorgum Jun. 27 at 1:05 PM

Healthcare starting to show real underlying strength here. Breakouts across $XBI and even $XLV approaching a key breakout level with breakouts on $JNJ and $ABBV. Even $GILD looks like it’s finding support after a long-term cup/base breakout. With semis extended, this could be an important defensive rotation to watch.

0 · Reply

FreedomQuestTrader Jun. 26 at 9:59 PM

** 💎 TODAY's PREMIUM PLAYS:** ----------------------------------- - 🟩 $JNJ - 6/26 250C @ 1.21 --> 5.60 | **+362.81%** | **$439.00** - 🟩 $INOD - 7/17 90P @ 8.54 --> 18.55 | **+117.21%** | **$1001.00** - 🟥 $BG - 7/17 115C @ 2.10 --> 1.74 | **-17.00%** | **-$35.70** ────────────────── Total Trades: **4** Today's Winrate: **50.00%** Total Gains: **+423.02%** Average Gains Per Call: **+105.76%** Total Profits: **$1,108.30** ────────────────── *Unlock All Our Trading Alerts TODAY ➡️ [SIGN UP FOR FREEDOM QUEST TRADES](https://www.launchpass.com/freedom-quest-trades/premium-member) ⬅️ Gain full access to premium calls from top trading analysts and more!

0 · Reply

GettnFibbywIT Jun. 26 at 9:06 PM

$JNJ Textbook

0 · Reply

TroyTiger Jun. 26 at 8:51 PM

$TGTX This is trading like a stock about to be bought out. I still think $JNJ is the one, as their stock is at all-time highs.

3 · Reply

BreakoutLife Jun. 26 at 8:50 PM

Nasdaq just logged its 5th straight down session - and this one is clearly being driven by a rapid sentiment reset in AI + semis. The catalyst: reports that OpenAI may delay its IPO into next year. That single headline is now being interpreted as a signal that the pace of AI infrastructure financing could slow, not just a corporate timing issue. That’s where the spillover starts: $MU -4% $INTC -3% $AMD -2% SoftBank -12% in Tokyo Kospi -5.8% - broad Asia risk-off move What you’re seeing is not just stock-specific weakness - it’s a global de-risking of the AI capex trade, with JPMorgan even flagging potential sustainability concerns if capital markets funding slows. And as usual in late-cycle rotations, money isn’t leaving the market - it’s rotating: $LLY +7%, $JNJ +3%, defensives, staples, utilities all catching flows. Adding macro pressure: Kashkari signaling potential additional rate hike risk due to inflation tied to geopolitical shocks - which doesn’t help growth duration multiples either. Feels like one of those moments where the AI trade doesn’t break… it just gets repriced.

0 · Reply

notreload_ai Jun. 26 at 7:54 PM

BREAKING: $ABBV, $LLY and $JNJ shares are on track to reach all-time highs.

0 · Reply

Market Cap	613.02B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	23.73
Forward PE	21.17
Profit Margin	28.46%
Debt to Equity Ratio	0.46

Volume	16,316,700
Avg Vol	8,309,220
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	98%
Beta	0.26
Analysts	Strong Sell
Price Target	$259.88